Investment Analysts’ Weekly Ratings Updates for Medifast (MED)

A number of firms have modified their ratings and price targets on shares of Medifast (NYSE: MED) recently:

  • 3/10/2018 – Medifast was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $97.00 price target on the stock. According to Zacks, “Medifast is a leading manufacturer and distributor of clinically proven healthy living products and programs. It is the brand recommended by more than 20,000 Doctors. Medifast produces, distributes, and sells weight loss and other health-related products through websites, multi-level marketing, telemarketing, franchised weight loss clinics, and medical professionals. The company launched OPTAVIA, an exclusive brand and product line sold through its community of independent Coaches who offer support and guidance to their Clients. In partnership with OPTAVIA Coaches , franchise partners, resellers and its Scientific Advisory Board, Medifast offers comprehensive wellness products and programs that focus on creating sustainable change by helping people learn to incorporate healthy habits into their lives. “
  • 3/8/2018 – Medifast had its price target raised by analysts at DA Davidson to $108.00. They now have a “buy” rating on the stock.
  • 3/7/2018 – Medifast was upgraded by analysts at Sidoti from a “neutral” rating to a “buy” rating.
  • 3/1/2018 – Medifast was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

Shares of Medifast Inc (NYSE MED) traded up $0.71 during midday trading on Friday, hitting $90.02. The company had a trading volume of 43,939 shares, compared to its average volume of 129,604. Medifast Inc has a 52-week low of $40.00 and a 52-week high of $92.91. The firm has a market capitalization of $1,076.06, a P/E ratio of 39.31, a PEG ratio of 1.85 and a beta of 0.61.

How to Become a New Pot Stock Millionaire

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, March 6th. The specialty retailer reported $0.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.12. Medifast had a return on equity of 26.39% and a net margin of 9.19%. The firm had revenue of $78.01 million during the quarter, compared to the consensus estimate of $73.48 million. During the same period last year, the company earned $0.34 earnings per share. The company’s revenue for the quarter was up 24.9% on a year-over-year basis. equities analysts anticipate that Medifast Inc will post 3.25 earnings per share for the current fiscal year.

In other Medifast news, Director Michael C. Macdonald sold 20,000 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $84.45, for a total value of $1,689,000.00. Following the completion of the sale, the director now owns 334,188 shares of the company’s stock, valued at $28,222,176.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.47% of the stock is currently owned by company insiders.

Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.

Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with's FREE daily email newsletter.

Leave a Reply